Bispecific antibodies: An innovative arsenal to hunt, grab and destroy cancer cells

Current Pharmaceutical Biotechnology

Volumn 16, Issue 8, 2015, Pages 670-683

  Grandjenette, Cindy ^a   Dicato, Mario ^a   Diederich, Marc ^b  

^a LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

^b Seoul National University   (South Korea)

Author keywords

Antibody engineering; Bispecific antibody; Cancer; Cell death; Clinical trials; Immunotherapy; NK cells; T cells

Indexed keywords

B7 ANTIGEN; BISPECIFIC ANTIBODY; CASPASE 3; CASPASE 8; CASPASE 9; CD16 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CYTOCHROME C; EPITHELIAL CELL ADHESION MOLECULE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FC RECEPTOR; GRANZYME B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; RANTES; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY ENGINEERING; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; NATURAL KILLER T CELL; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; T LYMPHOCYTE; ANIMAL; CELL DEATH; IMMUNOLOGY; IMMUNOTHERAPY; NATURAL KILLER CELL; NEOPLASMS;

ANIMALS; ANTIBODIES, BISPECIFIC; CELL DEATH; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS; T-LYMPHOCYTES;

EID: 84931834229     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201016666150505124037     Document Type: Article

References (117)

1. Byrne, H.; Conroy, P.J.; Whisstock, J.C.; O'Kennedy, R.J. A tale of two specificities: Bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol., 2013, 31(11), 621-632.
2. Chames, P.; Van Regenmortel, M.; Weiss, E.; Baty, D. Therapeutic antibodies: successes, limitations and hopes for the future. Brit. J. Pharmacol., 2009, 157(2), 220-233.
3. Koristka, S.; Cartellieri, M.; Theil, A.; Feldmann, A.; Arndt, C.; Stamova, S.; Michalk, I.; Topfer, K.; Temme, A.; Kretschmer, K.; Bornhauser, M.; Ehninger, G.; Schmitz, M.; Bachmann, M. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J. Immunol., 2012, 188(3), 1551-1558.
4. Chames, P.; Baty, D. Bispecific antibodies for cancer therapy. Curr. Opin. Drug Discov. Developm., 2009, 12(2), 276-283.
5. Graziano, R.F.; Guptill, P. Chemical production of bispecific antibodies. Methods Molecul. Biol., 2004, 283, 71-85.
6. Zeidler, R.; Reisbach, G.; Wollenberg, B.; Lang, S.; Chaubal, S.; Schmitt, B.; Lindhofer, H. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J. Immunol., 1999, 163(3), 1246- 1252.
7. Baeuerle, P.A.; Gires, O. EpCAM (CD326) finding its role in cancer. Brit. J. Cancer 2007, 96(3), 417-423.
8. Heiss, M.M.; Murawa, P.; Koralewski, P.; Kutarska, E.; Kolesnik, O.O.; Ivanchenko, V.V.; Dudnichenko, A.S.; Aleknaviciene, B.; Razbadauskas, A.; Gore, M.; Ganea-Motan, E.; Ciuleanu, T.; Wimberger, P.; Schmittel, A.; Schmalfeldt, B.; Burges, A.; Bokemeyer, C.; Lindhofer, H.; Lahr, A.; Parsons, S.L. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int. J. Cancer, 2010, 127(9), 2209- 2221.
9. Linke, R.; Klein, A.; Seimetz, D. Catumaxomab: clinical development and future directions. mAbs 2010, 2(2), 129-136.
10. Goéré, D.; Flament, C.; Rusakiewicz, S.; Poirier-Colame, V.; Kepp, O.; Martins, I.; Pesquet, J.; Eggermont, A.; Elias, D.; Chaput, N.; Zitvogel, L. Potent immunomodulatory effects of the trifunctional antibody catumaxomab. Cancer Res., 2013, 73(15), 4663-4673.
11. Atanackovic, D.; Reinhard, H.; Meyer, S.; Spock, S.; Grob, T.; Luetkens, T.; Yousef, S.; Cao, Y.; Hildebrandt, Y.; Templin, J.; Bartels, K.; Lajmi, N.; Stoiber, H.; Kroger, N.; Atz, J.; Seimetz, D.; Izbicki, J.R.; Bokemeyer, C. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Human Vaccines Immunotherapeut., 2013, 9(12), 2533-2542.
12. Jager, M.; Schoberth, A.; Ruf, P.; Hess, J.; Hennig, M.; Schmalfeldt, B.; Wimberger, P.; Strohlein, M.; Theissen, B.; Heiss, M.M.; Lindhofer, H. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer Res., 2012, 72(1), 24-32.
13. Berek, J.S.; Edwards, R.P.; Parker, L.P.; DeMars, L.R.; Herzog, T.J.; Lentz, S.S.; Morris, R.T.; Akerley, W.L.; Holloway, R.W.; Method, M.W.; Plaxe, S.C.; Walker, J.L.; Friccius-Quecke, H.; Krasner, C.N. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: A Phase II Study. Int. J. Gynecologic. Cancer, 2014, 24(9), 1583-1589.
14. Jager, M.; Schoberth, A.; Ruf, P.; Hess, J.; Lindhofer, H. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res., 2009, 69(10), 4270-4276.
15. Heiss, M.M.; Strohlein, M.A.; Jager, M.; Kimmig, R.; Burges, A.; Schoberth, A.; Jauch, K.W.; Schildberg, F.W.; Lindhofer, H. Immunotherapy of malignant ascites with trifunctional antibodies. Int. J. Cancer. Journal. Int. Du Cancer, 2005, 117(3), 435-443.
16. Stanglmaier, M.; Faltin, M.; Ruf, P.; Bodenhausen, A.; Schroder, P.; Lindhofer, H. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of Bcell lymphoma cells even with very low CD20 expression levels. Int. J. Cancer. J. Int. Du Cancer, 2008, 123(5), 1181-1189.
17. Cheson, B.D.; Leonard, J.P. Monoclonal antibody therapy for Bcell non-Hodgkin's lymphoma. New Engl. J. Med., 2008, 359(6), 613-626.
18. Buhmann, R.; Michael, S.; Juergen, H.; Horst, L.; Peschel, C.; Kolb, H.J. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: Study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. J. Translation. Med., 2013, 11, 160.
19. Lum, L.G.; Thakur, A.; Liu, Q.; Deol, A.; Al-Kadhimi, Z.; Ayash, L.; Abidi, M.H.; Pray, C.; Tomaszewski, E.N.; Steele, P.A.; Schalk, D.L.; Yano, H.; Mitchell, A.; Dufresne, M.; Uberti, J.P.; Ratanatharathorn, V. CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma. Biol. Blood Marrow Transplantat., 2013, 19(6), 925-933.
20. Lum, L.G.; Thakur, A.; Pray, C.; Kouttab, N.; Abedi, M.; Deol, A.; Colaiace, W.M.; Rathore, R., Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: A pilot study. Bone Marrow Transplantat., 2014, 49(1), 73-79.
21. Yankelevich, M.; Kondadasula, S.V.; Thakur, A.; Buck, S.; Cheung, N.K.; Lum, L.G. Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediat. Blood Cancer, 2012, 59(7), 1198-205.
22. Kufer, P.; Lutterbuse, R.; Baeuerle, P.A. A revival of bispecific antibodies. Trends Biotechnol., 2004, 22(5), 238-244.
23. Holliger, P.; Hudson, P.J. Engineered antibody fragments and the rise of single domains. Nature Biotechnol., 2005, 23(9), 1126-1136.
24. Nelson, A.L. Antibody fragments: Hope and hype. mAbs 2010, 2(1), 77-83.
25. Joosten, V.; Lokman, C.; Van Den Hondel, C. A.; Punt, P.J. The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. Microbial Cell Factories, 2003, 2(1), 1.
26. Kipriyanov, S.M.; Cochlovius, B.; Schafer, H.J.; Moldenhauer, G.; Bahre, A.; Le Gall, F.; Knackmuss, S.; Little, M. Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. J. Immunol., 2002, 169(1), 137-144.
27. Baum, V.; Buhler, P.; Gierschner, D.; Herchenbach, D.; Fiala, G.J.; Schamel, W.W.; Wolf, P.; Elsasser-Beile, U. Antitumor activities of PSMAxCD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy, 2013, 5(1), 27-38.
28. Feldmann, A.; Stamova, S.; Bippes, C.C.; Bartsch, H.; Wehner, R.; Schmitz, M.; Temme, A.; Cartellieri, M.; Bachmann, M. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats. The Prostate 2011, 71(9), 998-1011.
29. Mabry, R.; Snavely, M., Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles. IDrugs, 2010, 13(8), 543-549.
30. Acuto, O.; Michel, F. CD28-mediated co-stimulation: A quantitative support for TCR signalling. Nature Rev. Immunol., 2003, 3(12), 939-51.
31. Grosse-Hovest, L.; Hartlapp, I.; Marwan, W.; Brem, G.; Rammensee, H.G.; Jung, G. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur. J. Immunol., 2003, 33(5), 1334-1340.
32. Otz, T.; Grosse-Hovest, L.; Hofmann, M.; Rammensee, H.G.; Jung, G. A bispecific single-chain antibody that mediates target cellrestricted, supra-agonistic CD28 stimulation and killing of lymphoma cells. Leukemia 2009, 23(1), 71-77.
33. Beyersdorf, N.; Hanke, T.; Kerkau, T.; Hunig, T., Superagonistic anti-CD28 antibodies: Potent activators of regulatory T cells for the therapy of autoimmune diseases. Annals of the rheumatic diseases 2005, 64(Suppl 4), iv91-5.
34. Elflein, K.; Rodriguez-Palmero, M.; Kerkau, T.; Hunig, T. Rapid recovery from T lymphopenia by CD28 superagonist therapy. Blood 2003, 102(5), 1764-1770.
35. Suntharalingam, G.; Perry, M.R.; Ward, S.; Brett, S.J.; Castello- Cortes, A.; Brunner, M.D.; Panoskaltsis, N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. New Engl. J. Med., 2006, 355(10), 1018-1028.
36. Grosse-Hovest, L.; Wick, W.; Minoia, R.; Weller, M.; Rammensee, H.G.; Brem, G.; Jung, G. Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo. Int. J. Cancer. J. Int. Du Cancer, 2005, 117(6), 1060-1064.
37. Fortmuller, K.; Alt, K.; Gierschner, D.; Wolf, P.; Baum, V.; Freudenberg, N.; Wetterauer, U.; Elsasser-Beile, U.; Buhler, P. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA x CD3 bispecific single-chain diabody. The Prostate, 2011, 71(6), 588-596.
38. Baeuerle, P.A.; Kufer, P.; Bargou, R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr. Opin. Molecul. Therapeut., 2009, 11(1), 22-30.
39. Brischwein, K.; Parr, L.; Pflanz, S.; Volkland, J.; Lumsden, J.; Klinger, M.; Locher, M.; Hammond, S.A.; Kiener, P.; Kufer, P.; Schlereth, B.; Baeuerle, P.A. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J. Immunotherap., 2007, 30(8), 798-807.
40. Wickramasinghe, D. Tumor and T cell engagement by BiTE. Discov. Med., 2013, 16(88), 149-152.
41. Choi, B.D.; Cai, M.; Bigner, D.D.; Mehta, A.I.; Kuan, C.T.; Sampson, J.H. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin. Biologic. Therap., 2011, 11(7), 843-853.
42. Wong, R.; Pepper, C.; Brennan, P.; Nagorsen, D.; Man, S.; Fegan, C. Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica, 2013, 98(12), 1930- 1938.
43. Topp, M.S.; Gokbuget, N.; Zugmaier, G.; Degenhard, E.; Goebeler, M.E.; Klinger, M.; Neumann, S. A.; Horst, H. A.; Raff, T.; Viardot, A.; Stelljes, M.; Schaich, M.; Kohne-Volland, R.; Bruggemann, M.; Ottmann, O. G.; Burmeister, T.; Baeuerle, P.A.; Nagorsen, D.; Schmidt, M.; Einsele, H.; Riethmuller, G.; Kneba, M.; Hoelzer, D.; Kufer, P.; Bargou, R.C. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood, 2012, 120(26), 5185-5187.
44. Topp, M.S.; Gokbuget, N.; Zugmaier, G.; Klappers, P.; Stelljes, M.; Neumann, S.; Viardot, A.; Marks, R.; Diedrich, H.; Faul, C.; Reichle, A.; Horst, H.A.; Bruggemann, M.; Wessiepe, D.; Holland, C.; Alekar, S.; Mergen, N.; Einsele, H.; Hoelzer, D.; Bargou, R.C. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory b-precursor acute lymphoblastic leukemia. J. Clin. Oncol., 2014.
45. Topp, M.S.; Kufer, P.; Gokbuget, N.; Goebeler, M.; Klinger, M.; Neumann, S.; Horst, H.A.; Raff, T.; Viardot, A.; Schmid, M.; Stelljes, M.; Schaich, M.; Degenhard, E.; Kohne-Volland, R.; Bruggemann, M.; Ottmann, O.; Pfeifer, H.; Burmeister, T.; Nagorsen, D.; Schmidt, M.; Lutterbuese, R.; Reinhardt, C.; Baeuerle, P.A.; Kneba, M.; Einsele, H.; Riethmuller, G.; Hoelzer, D.; Zugmaier, G.; Bargou, R.C. Targeted therapy with the T-cellengaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol., 2011, 29(18), 2493-2498.
46. Klinger, M.; Brandl, C.; Zugmaier, G.; Hijazi, Y.; Bargou, R.C.; Topp, M.S.; Gokbuget, N.; Neumann, S.; Goebeler, M.; Viardot, A.; Stelljes, M.; Bruggemann, M.; Hoelzer, D.; Degenhard, E.; Nagorsen, D.; Baeuerle, P.A.; Wolf, A.; Kufer, P. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood, 2012, 119(26), 6226-633.
47. Friedrich, M.; Raum, T.; Lutterbuese, R.; Voelkel, M.; Deegen, P.; Rau, D.; Kischel, R.; Hoffmann, P.; Brandl, C.; Schuhmacher, J.; Mueller, P.; Finnern, R.; Fuergut, M.; Zopf, D.; Slootstra, J.W.; Baeuerle, P.A.; Rattel, B.; Kufer, P. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with nonhuman primate antigens. Molecul. Cancer Therapeut., 2012, 11(12), 2664-2673.
48. Brischwein, K.; Schlereth, B.; Guller, B.; Steiger, C.; Wolf, A.; Lutterbuese, R.; Offner, S.; Locher, M.; Urbig, T.; Raum, T.; Kleindienst, P.; Wimberger, P.; Kimmig, R.; Fichtner, I.; Kufer, P.; Hofmeister, R.; da Silva, A.J.; Baeuerle, P.A. MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Molecul. Immunol., 2006, 43(8), 1129-1143.
49. Amann, M.; Friedrich, M.; Lutterbuese, P.; Vieser, E.; Lorenczewski, G.; Petersen, L.; Brischwein, K.; Kufer, P.; Kischel, R.; Baeuerle, P.A.; Schlereth, B. Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAMexpressing lymphocytes that is absent in humans. Cancer Immunol., Immunotherap.,: CII 2009, 58(1), 95-109.
50. Herrmann, I.; Baeuerle, P.A.; Friedrich, M.; Murr, A.; Filusch, S.; Ruttinger, D.; Majdoub, M.W.; Sharma, S.; Kufer, P.; Raum, T.; Munz, M. Highly efficient elimination of colorectal tumorinitiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. PloS One, 2010, 5(10), e13474.
51. Guimaraes, F.; Guven, H.; Donati, D.; Christensson, B.; Ljunggren, H.G.; Bejarano, M.T.; Dilber, M.S. Evaluation of ex vivo expanded human NK cells on antileukemia activity in SCID-beige mice. Leukemia, 2006, 20(5), 833-839.
52. Miller, J.S.; Soignier, Y.; Panoskaltsis-Mortari, A.; McNearney, S.A.; Yun, G.H.; Fautsch, S.K.; McKenna, D.; Le, C.; Defor, T.E.; Burns, L.J.; Orchard, P.J.; Blazar, B.R.; Wagner, J.E.; Slungaard, A.; Weisdorf, D.J.; Okazaki, I.J.; McGlave, P.B. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 2005, 105(8), 3051-3057.
53. Cooper, M.A.; Fehniger, T.A.; Caligiuri, M.A. The biology of human natural killer-cell subsets. Trends Immunol., 2001, 22(11), 633-640.
54. Sconocchia, G.; Titus, J. A.; Segal, D.M. Signaling pathways regulating CD44-dependent cytolysis in natural killer cells. Blood, 1997, 90(2), 716-725.
55. Alderson, K.L.; Sondel, P.M. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J. Biomed. Biotechnol., 2011, 2011, 379123.
56. Scott, A.M.; Wolchok, J.D.; Old, L.J. Antibody therapy of cancer. Nat. Rev. Cancer, 2012, 12(4), 278-287.
57. Gleason, M.K.; Verneris, M.R.; Todhunter, D.A.; Zhang, B.; McCullar, V.; Zhou, S.X.; Panoskaltsis-Mortari, A.; Weiner, L.M.; Vallera, D.A.; Miller, J.S. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Molecul. Cancer Therapeut., 2012, 11(12), 2674-2684.
58. Reiners, K.S.; Kessler, J.; Sauer, M.; Rothe, A.; Hansen, H.P.; Reusch, U.; Hucke, C.; Kohl, U.; Durkop, H.; Engert, A.; von Strandmann, E.P. Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Molecul. Therap., 2013, 21(4), 895-903.
59. Vallera, D.A.; Zhang, B.; Gleason, M.K.; Oh, S.; Weiner, L.M.; Kaufman, D.S.; McCullar, V.; Miller, J.S.; Verneris, M.R. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother. Radiopharmaceut., 2013, 28(4), 274-282.
60. Gleason, M.K.; Ross, J.A.; Warlick, E.D.; Lund, T.C.; Verneris, M.R.; Wiernik, A.; Spellman, S.; Haagenson, M.D.; Lenvik, A.J.; Litzow, M.R.; Epling-Burnette, P.K.; Blazar, B.R.; Weiner, L.M.; Weisdorf, D.J.; Vallera, D.A.; Miller, J.S. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood, 2014, 123(19), 3016-26.
61. Singer, H.; Kellner, C.; Lanig, H.; Aigner, M.; Stockmeyer, B.; Oduncu, F.; Schwemmlein, M.; Stein, C.; Mentz, K.; Mackensen, A.; Fey, G.H. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J. Immunotherap., 2010, 33(6), 599-608.
62. Wiernik, A.; Foley, B.; Zhang, B.; Verneris, M.R.; Warlick, E.; Gleason, M. K.; Ross, J. A.; Luo, X.; Weisdorf, D. J.; Walcheck, B.; Vallera, D.A.; Miller, J.S., Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clinical Cancer Res., 2013, 19(14), 3844-55.
63. Moore, P.A.; Zhang, W.; Rainey, G.J.; Burke, S.; Li, H.; Huang, L.; Gorlatov, S.; Veri, M.C.; Aggarwal, S.; Yang, Y.; Shah, K.; Jin, L.; Zhang, S.; He, L.; Zhang, T.; Ciccarone, V.; Koenig, S.; Bonvini, E.; Johnson, S. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 2011, 117(17), 4542-4551.
64. Johnson, S.; Burke, S.; Huang, L.; Gorlatov, S.; Li, H.; Wang, W.; Zhang, W.; Tuaillon, N.; Rainey, J.; Barat, B.; Yang, Y.; Jin, L.; Ciccarone, V.; Moore, P.A.; Koenig, S.; Bonvini, E. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J. Molecul. Biol., 2010, 399(3), 436-449.
65. Veri, M. C.; Burke, S.; Huang, L.; Li, H.; Gorlatov, S.; Tuaillon, N.; Rainey, G.J.; Ciccarone, V.; Zhang, T.; Shah, K.; Jin, L.; Ning, L.; Minor, T.; Moore, P.A.; Koenig, S.; Johnson, S.; Bonvini, E. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheumat., 2010, 62(7), 1933- 1943.
66. Renner, C.; Held, G.; Ohnesorge, S.; Bauer, S.; Gerlach, K.; Pfitzenmeier, J.P.; Pfreundschuh, M. Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells. Cancer Immunol., Immunotherap.: CII 1997, 44(2), 70-76.
67. Sen, M.; Wankowski, D.M.; Garlie, N.K.; Siebenlist, R.E.; Van Epps, D.; LeFever, A.V.; Lum, L.G. Use of anti-CD3 x anti- HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. J. Hematotherap. Stem Cell Res., 2001, 10(2), 247-260.
68. Thakur, A.; Norkina, O.; Lum, L.G. In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells. Cancer Immunol., Immunotherap.: CII 2011, 60(12), 1707-1720.
69. Grabert, R.C.; Cousens, L.P.; Smith, J.A.; Olson, S.; Gall, J.; Young, W.B.; Davol, P.A.; Lum, L.G. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin. Cancer Res., 2006, 12 (2), 569-576.
70. Gall, J.M.; Davol, P.A.; Grabert, R.C.; Deaver, M.; Lum, L.G. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. Experimental hematol., 2005, 33(4), 452-459.
71. Reusch, U.; Sundaram, M.; Davol, P.A.; Olson, S.D.; Davis, J.B.; Demel, K.; Nissim, J.; Rathore, R.; Liu, P.Y.; Lum, L.G. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin. Cancer Res., 2006, 12(1), 183-190.
72. Thakur, A.; Schalk, D.; Tomaszewski, E.; Kondadasula, S. V.; Yano, H.; Sarkar, F. H.; Lum, L. G., Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway. J. Translation. Med., 2013, 11, 35.
73. Vaishampayan, U.; Thakur, A.; Rathore, R.; Kouttab, N.; Lum, L. G. Phase I study of anti-CD3 x Anti-Her2 bispecific antibody in metastatic castrate resistant prostate cancer patients. Prostate cancer 2015, 2015, 285193.
74. Lum, L. G.; Thakur, A. Targeting T cells with bispecific antibodies for cancer therapy. BioDrugs: Clin. Immunotherapeut., Biopharmaceut. Gene Therap., 2011, 25(6), 365-379.
75. Riechelmann, H.; Wiesneth, M.; Schauwecker, P.; Reinhardt, P.; Gronau, S.; Schmitt, A.; Schroen, C.; Atz, J.; Schmitt, M. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial. Cancer Immunol, Immunotherap.: CII 2007, 56 (9), 1397-1406.
76. Weiner, L. M.; Clark, J. I.; Davey, M.; Li, W.S.; Garcia de Palazzo, I.; Ring, D.B.; Alpaugh, R.K. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res., 1995, 55(20), 4586-4593.
77. Cao, Y.; Lam, L., Bispecific antibody conjugates in therapeutics. Adv. Drug Deliv. Rev., 2003, 55(2), 171-197.
78. Hwu, P.; Yang, J.C.; Cowherd, R.; Treisman, J.; Shafer, G.E.; Eshhar, Z.; Rosenberg, S.A. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res., 1995, 55(15), 3369-3373.
79. Eshhar, Z.; Fitzer-Attas, C.J. Tyrosine kinase chimeras for antigenselective T-body therapy. Adv. Drug Deliv. Rev., 1998, 31(1-2), 171-182.
80. Ramos, C.A.; Savoldo, B.; Dotti, G. CD19-CAR trials. Cancer J., 2014, 20(2), 112-118.
81. Kalos, M.; Levine, B.L.; Porter, D.L.; Katz, S.; Grupp, S.A.; Bagg, A.; June, C.H. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Translation. Med., 2011, 3(95), 95ra73.
82. Ruella, M.; Kalos, M. Adoptive immunotherapy for cancer. Immunologic. Rev., 2014, 257(1), 14-38.
83. Lee, D.W.; Gardner, R.; Porter, D.L.; Louis, C.U.; Ahmed, N.; Jensen, M.; Grupp, S.A.; Mackall, C.L. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014, 124(2), 188-195.
84. Huse, M.; Catherine Milanoski, S.; Abeyweera, T.P. Building tolerance by dismantling synapses: inhibitory receptor signaling in natural killer cells. Immunologic. Rev., 2013, 251(1), 143-153.
85. Monks, C.R.; Freiberg, B.A.; Kupfer, H.; Sciaky, N.; Kupfer, A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature, 1998, 395(6697), 82-86.
86. Feldmann, A.; Arndt, C.; Topfer, K.; Stamova, S.; Krone, F.; Cartellieri, M.; Koristka, S.; Michalk, I.; Lindemann, D.; Schmitz, M.; Temme, A.; Bornhauser, M.; Ehninger, G.; Bachmann, M. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J. Immunol., 2012, 189(6), 3249-3259.
87. Zheng, P.; Sarma, S.; Guo, Y.; Liu, Y. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors. Cancer Res., 1999, 59(14), 3461-3467.
88. Nagorsen, D.; Baeuerle, P.A. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Experiment. Cell Res., 2011, 317(9), 1255-1260.
89. Buhler, P.; Molnar, E.; Dopfer, E.P.; Wolf, P.; Gierschner, D.; Wetterauer, U.; Schamel, W.W.; Elsasser-Beile, U. Targetdependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells. J. Immunotherap., 2009, 32(6), 565-573.
90. Gruen, M.; Bommert, K.; Bargou, R. C., T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent. Cancer Immunol., Immunotherap., CII 2004, 53(7), 625-632.
91. Haas, C.; Krinner, E.; Brischwein, K.; Hoffmann, P.; Lutterbuse, R.; Schlereth, B.; Kufer, P.; Baeuerle, P.A. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology, 2009, 214(6), 441-453.
92. Henkart, P.A. Lymphocyte-mediated cytotoxicity: Two pathways and multiple effector molecules. Immunity, 1994, 1(5), 343-346.
93. Almeida, C.R.; Davis, D.M. Segregation of HLA-C from ICAM-1 at NK cell immune synapses is controlled by its cell surface density. J. Immunol., 2006, 177(10), 6904-6910.
94. Bossi, G.; Griffiths, G.M. CTL secretory lysosomes: Biogenesis and secretion of a harmful organelle. Seminars Immunol., 2005, 17(1), 87-94.
95. Orange, J.S.; Harris, K.E.; Andzelm, M.M.; Valter, M.M.; Geha, R.S.; Strominger, J.L. The mature activating natural killer cell immunologic synapse is formed in distinct stages. Proc. Natl. Acad. Sci. USA., 2003, 100(24), 14151-14156.
96. Lieberman, J. The ABCs of granule-mediated cytotoxicity: New weapons in the arsenal. Nat. Rev. Immunol., 2003, 3(5), 361-370.
97. Waterhouse, N.J.; Sedelies, K.A.; Trapani, J.A. Role of Bidinduced mitochondrial outer membrane permeabilization in granzyme B-induced apoptosis. Immunol. Cell Biol., 2006, 84(1), 72-78.
98. Adrain, C.; Murphy, B.M.; Martin, S.J. Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B. J. Biologic. Chem., 2005, 280(6), 4663-4673.
99. Marsden, V.S.; Strasser, A. Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. Ann. Rev. Immunol., 2003, 21, 71-105.
100. Wang, G.Q.; Gastman, B.R.; Wieckowski, E.; Goldstein, L.A.; Gambotto, A.; Kim, T.H.; Fang, B.; Rabinovitz, A.; Yin, X.M.; Rabinowich, H. A role for mitochondrial Bak in apoptotic response to anticancer drugs. J. Biologic. Chem., 2001, 276(36), 34307- 34317.
101. Li, P.; Nijhawan, D.; Budihardjo, I.; Srinivasula, S. M.; Ahmad, M.; Alnemri, E.S.; Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 1997, 91(4), 479-489.
102. Thomas, D.A.; Du, C.; Xu, M.; Wang, X.; Ley, T.J. DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. Immunity, 2000, 12(6), 621-632.
103. Wischhusen, J.; Schneider, D.; Mittelbronn, M.; Meyermann, R.; Engelmann, H.; Jung, G.; Wiendl, H.; Weller, M. Death receptormediated apoptosis in human malignant glioma cells: modulation by the CD40/CD40L system. J. Neuroimmunol., 2005, 162(1-2), 28-42.
104. Locksley, R.M.; Killeen, N.; Lenardo, M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell, 2001, 104(4), 487-501.
105. Smyth, M.J.; Cretney, E.; Kelly, J.M.; Westwood, J.A.; Street, S.E.; Yagita, H.; Takeda, K.; van Dommelen, S. L.; Degli-Esposti, M.A.; Hayakawa, Y. Activation of NK cell cytotoxicity. Molecul. Immunol., 2005, 42(4), 501-510.
106. Schutze, S.; Tchikov, V.; Schneider-Brachert, W. Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nat. Re. Molecul. Cell Biol. 2008, 9(8), 655-662.
107. Lazar, G.A.; Dang, W.; Karki, S.; Vafa, O.; Peng, J.S.; Hyun, L.; Chan, C.; Chung, H.S.; Eivazi, A.; Yoder, S. C.; Vielmetter, J.; Carmichael, D.F.; Hayes, R.J.; Dahiyat, B.I. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA, 2006, 103(11), 4005-4010.
108. Nimmerjahn, F.; Ravetch, J.V. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol., 2007, 19(2), 239-245.
109. Macor, P.; Secco, E.; Mezzaroba, N.; Zorzet, S.; Durigutto, P.; Gaiotto, T.; De Maso, L.; Biffi, S.; Garrovo, C.; Capolla, S.; Tripodo, C.; Gattei, V.; Marzari, R.; Tedesco, F.; Sblattero, D. Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. Leukemia, 2014.
110. Zeidler, R.; Mysliwietz, J.; Csanady, M.; Walz, A.; Ziegler, I.; Schmitt, B.; Wollenberg, B.; Lindhofer, H. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Brit. J. Cancer, 2000, 83(2), 261-266.
111. Leibson, P.J. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity, 1997, 6(6), 655-661.
112. Ricklin, D.; Hajishengallis, G.; Yang, K.; Lambris, J. D., Complement: A key system for immune surveillance and homeostasis. Nat. Immunol., 2010, 11(9), 785-797.
113. Desjarlais, J.R.; Lazar, G.A.; Zhukovsky, E.A.; Chu, S.Y. Optimizing engagement of the immune system by anti-tumor antibodies: An engineer's perspective. Drug Discov. Today, 2007, 12(21-22), 898-910.
114. Segal, D.M.; Weiner, G.J.; Weiner, L.M. Introduction: Bispecific antibodies. J. Immunologic. Methods, 2001, 248(1-2), 1-6.
115. Carter, P. Bispecific human IgG by design. J. Immunologic. Methods, 2001, 248(1-2), 7-15.
116. Baeuerle, P.A.; Kufer, P.; Lutterbuse, R. Bispecific antibodies for polyclonal T-cell engagement. Curr. Opin. Molecul. Therapeut., 2003, 5(4), 413-419.
117. Smyth, M.J.; Strobl, S.L.; Young, H.A.; Ortaldo, J.R.; Ochoa, A.C. Regulation of lymphokine-activated killer activity and poreforming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta. J. Immunol., 1991, 146(10), 3289-3297.